Clinical trialPhase 1Recruiting
A Study of NWY001 in Subjects With Advanced Solid Tumors
A Multicenter, Non-randomized, Open-label, Multiple-Dose Phase I Study of NWY001, in Subjects With Advanced Solid Tumors
- Outcome
- Ongoing
- Phase
- Phase 1
- Status
- Recruiting
- Study type
- Interventional
- Start
- 5 January 2024
- Expected end
- May 2028
- Enrollment
- 196 participants
- Sites
- 1
- Primary outcomes
- Dose-limiting toxicity (DLT); Incidence of adverse events (AEs)
- Sponsor type
- Industry
- Results posted
- No
- Last update
- 16 July 2024
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
This is a Phase 1, single-arm, open-label, dose-escalation study in patients with advanced solid tumors including 2 parts: Part 1: Dose-Escalation Part Part 2: Dose-Expansion Part
Detailed description public domain (ClinicalTrials.gov)
Part 1: Patients with advanced solid tumors that has relapsed from or is refractory to standard therapy or for which no standard therapy exists will be enrolled in different cohorts. Part 2: Recommended Phase 2 dose (RP2D) of NWY001 will be given to all patients enrolled in this part.